Lupin v. Exeltis: Federal Circuit Remands Drospirenone Patent Dispute

Case Overview

The Parties

Patents at Issue

This dispute involves 15 U.S. patents, covering formulation, dosing regimen, and therapeutic application aspects of drospirenone oral contraceptive tablets. The patent family reflects a layered prosecution strategy designed to erect broad exclusivity around the SLYND® franchise.

• • US10849857B2 — Covers formulation aspects of drospirenone
• • US11123299B2 — Relates to specific dosing regimens
• • US10179140B2 — Addresses therapeutic applications
• • US9603860B2 — Related to drospirenone composition
• • US11439598B2 — Specific pharmaceutical compositions
• • US10603281B2 — Further aspects of drospirenone formulation
• • US11291633B2 — Methods of administration
• • US10987364B1 — Drospirenone dosage forms
• • US11413249B2 — Improved contraceptive methods
• • US11291632B2 — Formulation stability
• • US11491113B1 — Novel drospirenone derivatives
• • US11351122B1 — Contraceptive methods and uses
• • US11452695B2 — Pharmaceutical compositions of drospirenone
• • US11478487B1 — Sustained release formulations
• • US11504334B2 — Manufacturing processes

Litigation Timeline & Procedural History

The appeal was filed on **December 3, 2024**, and closed **September 29, 2025** — a duration of approximately **300 days**, which is relatively compressed for Federal Circuit pharmaceutical patent appeals. The matter originated as an infringement action at the **district court level** before reaching the **Court of Appeals for the Federal Circuit**, headquartered in the District of Columbia. The Federal Circuit’s jurisdiction over patent appeals is exclusive, making all appellate patent rulings in this forum nationally authoritative.

The 300-day timeline suggests the appeal may have been resolved on motion practice or procedural grounds rather than full merits briefing and oral argument — consistent with the remand outcome, which did not address substantive infringement or validity questions. The remand itself references an unresolved **motion to amend the final judgment** at the district court level — a procedural posture that indicates the appeal was premature or that changed circumstances required the lower court’s attention before the Federal Circuit could complete appellate review.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a **remand order** rather than a merits decision. The court’s order states:

*”The motions are granted to the extent that the appeal is remanded to the district court to rule on the parties’ motion to amend the final judgment, which this court leaves to the district court.”*

The parties were directed to **bear their own costs** — a neutral cost allocation suggesting neither side achieved a clear procedural victory. No damages award, injunctive relief grant, or validity/infringement finding was issued at the appellate level.

Key Legal Issues

The Federal Circuit cited **Ohio Willow Wood Co. v. Thermo-Ply, Inc., 629 F.3d 1374, 1375 (Fed. Cir. 2011)** as the controlling precedent for its remand. That decision established that when parties seek to amend a final judgment at the district court level while an appeal is pending, the appropriate course is often to remand the case so the district court can address the amendment motion with full context before the Federal Circuit conducts merits review.

This procedural mechanism reflects an important principle: **appellate courts will not rule on underlying merits when foundational judgment questions remain unresolved**. The existence of a motion to amend the final judgment suggests that material facts or legal conclusions from the district court proceeding may be in flux — potentially affecting infringement findings, claim scope, or damages calculations across any of the 15 patents at issue.

Critically, the Federal Circuit’s order does **not** resolve questions of validity or infringement for any of the 15 drospirenone patents. Those determinations remain pending, depending on how the district court resolves the amendment motion.